Your browser doesn't support javascript.
loading
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.
Mustacchi, G; Puglisi, F; Molino, A M; Crivellari, D; Ghiotto, C; Ferro, A; Brunello, A; Saracchini, S; Turazza, M; Cretella, E; Iop, A; Malagoli, M; Stefani, M.
Affiliation
  • Mustacchi G; Medical Oncology, University of Trieste, Via Lucrezio 9, 34134 Trieste, Italy.
Future Oncol ; 11(10): 1493-500, 2015.
Article in En | MEDLINE | ID: mdl-25708426
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Future Oncol Year: 2015 Document type: Article Affiliation country: Italia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Future Oncol Year: 2015 Document type: Article Affiliation country: Italia